Vor Bio grants CEO Jean-Paul Kress an option to purchase 83.3 million shares at $0.89, vesting over four years. Vor Bio, a biotechnology company specializing in autoimmune disease treatments, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results